DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: AMG 706

First Posted Date: 2007-03-19

Last Posted Date: 2011-01-21

Lead Sponsor: Amgen

Target Recruit Count: 49

Registration Number: NCT00448786

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Phase 2

Completed

Conditions: Head and Neck Cancer
Metastases
Oncology
Tumors
Cancer
Carcinoma
Squamous Cell Carcinoma
Metastatic Cancer
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Panitumumab

First Posted Date: 2007-03-12

Last Posted Date: 2022-10-05

Lead Sponsor: Amgen

Target Recruit Count: 52

Registration Number: NCT00446446

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: AMG 714

First Posted Date: 2007-03-05

Last Posted Date: 2016-01-20

Lead Sponsor: Amgen

Target Recruit Count: 22

Registration Number: NCT00443326

Ancillary Study to Protocol 20060104

Completed

Conditions: Rheumatoid Arthritis

Interventions: Procedure: Blood draw

First Posted Date: 2007-02-26

Last Posted Date: 2008-03-21

Lead Sponsor: Amgen

Target Recruit Count: 50

Registration Number: NCT00439894

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Darbepoetin Alfa

First Posted Date: 2007-02-19

Last Posted Date: 2011-01-21

Lead Sponsor: Amgen

Target Recruit Count: 114

Registration Number: NCT00436995

Phase II Study to Evaluate the Efficacy of AMG 317

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: AMG 317 150 mg
Biological: AMG 317 75 mg
Biological: Placebo
Biological: AMG 317 300 mg

First Posted Date: 2007-02-19

Last Posted Date: 2016-03-23

Lead Sponsor: Amgen

Target Recruit Count: 294

Registration Number: NCT00436670

Phase 2 AMG 714 in Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2007-02-12

Last Posted Date: 2007-12-28

Lead Sponsor: Amgen

Target Recruit Count: 180

Registration Number: NCT00433875

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
Anemia

Interventions: Drug: Cinacalcet

First Posted Date: 2007-02-05

Last Posted Date: 2013-04-24

Lead Sponsor: Amgen

Target Recruit Count: 71

Registration Number: NCT00431496

A Phase II Study to Treat Advanced Malignant Glioma

Phase 2

Completed

Conditions: Advanced Malignant Glioma

Interventions: Drug: AMG 102 at 10 mg/kg
Drug: AMG 102 at 20 mg/kg

First Posted Date: 2007-01-29

Last Posted Date: 2015-04-27

Lead Sponsor: Amgen

Target Recruit Count: 61

Registration Number: NCT00427440

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2007-01-22

Last Posted Date: 2013-05-13

Lead Sponsor: Amgen

Target Recruit Count: 115

Registration Number: NCT00425035

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy